A phase II randomized study of adjuvant imatinib versus high-dose interferon alpha-2b for resected high-risk c-kit mutated melanoma.
Lu Si
No relevant relationships to disclose
Xuan Wang
No relevant relationships to disclose
Yan Kong
No relevant relationships to disclose
Bin Lian
No relevant relationships to disclose
Zhi Hong Chi
No relevant relationships to disclose
Chuan Liang Cui
No relevant relationships to disclose
Xi Nan Sheng
No relevant relationships to disclose
Li Li Mao
No relevant relationships to disclose
Bi Xia Tang
No relevant relationships to disclose
Si Ming Li
No relevant relationships to disclose
Qiao Xie Yan
No relevant relationships to disclose
Jun Guo
No relevant relationships to disclose